Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.

@article{Rathkopf2011PhaseID,
  title={Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.},
  author={Dana E. Rathkopf and Glenn X Liu and Michael Anthony Carducci and Mario A. Eisenberger and Aseem Anand and Michael J Morris and Susan F. Slovin and Yasutsuna Sasaki and Shunji Takahashi and Seiichiro Ozono and Nga Kit Eliza Fung and Shinta Cheng and Jinping Gan and Marco M. Gottardis and Mary T. Obermeier and Jyotsna Reddy and Steven Zhang and Blisse J Vakkalagadda and Leila Alland and George Wilding and Howard I. Scher},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 4},
  pages={880-7}
}
PURPOSE BMS-641988 is an androgen receptor antagonist with increased potency relative to bicalutamide in both in vitro and in vivo prostate cancer models. A first-in-man phase I study was conducted to define the safety and tolerability of oral BMS-641988 in patients with castration-resistant prostate cancer (CRPC). EXPERIMENTAL DESIGN Doses were escalated from 5 to 150 mg based on discrete pharmacokinetic parameters in cohorts of three to six subjects. After establishing safety with 20 mg of… CONTINUE READING
15 Extracted Citations
12 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 15 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 12 references

Safety, pharmacokinetics, and efficacy of TAK-700 in castrationresistant, metastatic prostate cancer: A phase I/II, open-label study

  • R Dreicer, DB Agus, GR MacVicar, D MacLean, T Zhang, WM. Stadler
  • Research. on April
  • 2010
Highly Influential
11 Excerpts

Similar Papers

Loading similar papers…